296 related articles for article (PubMed ID: 27555149)
1. A rare genetic variant of the ryanodine receptor in a suspected malignant hyperthermia susceptible patient.
MacKay EJ; Wilkerson C; Kraeva N; Rosenberg H; Kennedy T
J Clin Anesth; 2016 Sep; 33():144-6. PubMed ID: 27555149
[TBL] [Abstract][Full Text] [Related]
2. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.
Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB
Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394
[TBL] [Abstract][Full Text] [Related]
3. [Malignant hyperthermia].
Metterlein T; Schuster F; Graf BM; Anetseder M
Anaesthesist; 2014 Dec; 63(12):908-18. PubMed ID: 25384957
[TBL] [Abstract][Full Text] [Related]
4. [Malignant hyperthermia--a hereditary and potentially life-threatening condition].
Haugen T; Toft M; Müller CR; Aasly J
Tidsskr Nor Laegeforen; 2005 Oct; 125(20):2792-4. PubMed ID: 16244682
[TBL] [Abstract][Full Text] [Related]
5. Malignant hyperthermia: a pharmacogenetic disorder.
Stratman RC; Flynn JD; Hatton KW
Orthopedics; 2009 Nov; 32(11):835. PubMed ID: 19902883
[No Abstract] [Full Text] [Related]
6. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia.
Galli L; Orrico A; Lorenzini S; Censini S; Falciani M; Covacci A; Tegazzin V; Sorrentino V
Hum Mutat; 2006 Aug; 27(8):830. PubMed ID: 16835904
[TBL] [Abstract][Full Text] [Related]
7. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
8. Increasing the number of diagnostic mutations in malignant hyperthermia.
Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T
Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329
[TBL] [Abstract][Full Text] [Related]
9. Identification of malignant hyperthermia-susceptible ryanodine receptor type 1 gene (RYR1) mutations in a child who died in a car after exposure to a high environmental temperature.
Nishio H; Sato T; Fukunishi S; Tamura A; Iwata M; Tsuboi K; Suzuki K
Leg Med (Tokyo); 2009 May; 11(3):142-3. PubMed ID: 19223216
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
[TBL] [Abstract][Full Text] [Related]
11. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
12. Delayed onset of malignant hyperthermia without creatine kinase elevation in a geriatric, ryanodine receptor type 1 gene compound heterozygous patient.
Newmark JL; Voelkel M; Brandom BW; Wu J
Anesthesiology; 2007 Aug; 107(2):350-3. PubMed ID: 17667581
[No Abstract] [Full Text] [Related]
13. Is there a link between malignant hyperthermia and exertional heat illness?
Muldoon S; Deuster P; Brandom B; Bunger R
Exerc Sport Sci Rev; 2004 Oct; 32(4):174-9. PubMed ID: 15604937
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?
Robinson RL; Anetseder MJ; Brancadoro V; van Broekhoven C; Carsana A; Censier K; Fortunato G; Girard T; Heytens L; Hopkins PM; Jurkat-Rott K; Klinger W; Kozak-Ribbens G; Krivosic R; Monnier N; Nivoche Y; Olthoff D; Rueffert H; Sorrentino V; Tegazzin V; Mueller CR
Eur J Hum Genet; 2003 Apr; 11(4):342-8. PubMed ID: 12700608
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
Girard T; Urwyler A; Censier K; Mueller CR; Zorzato F; Treves S
Hum Mutat; 2001 Oct; 18(4):357-8. PubMed ID: 11668625
[TBL] [Abstract][Full Text] [Related]
16. Screening of the ryanodine 1 gene for malignant hyperthermia causative mutations by high resolution melt curve analysis.
Broman M; Heinecke K; Islander G; Schuster F; Glahn K; Bodelsson M; Treves S; Müller C
Anesth Analg; 2011 Nov; 113(5):1120-8. PubMed ID: 21965348
[TBL] [Abstract][Full Text] [Related]
17. Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: A 25-year retrospective study.
Bamaga AK; Riazi S; Amburgey K; Ong S; Halliday W; Diamandis P; Guerguerian AM; Dowling JJ; Yoon G
Neuromuscul Disord; 2016 Mar; 26(3):201-6. PubMed ID: 26951757
[TBL] [Abstract][Full Text] [Related]
18. Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation.
Fagerlund TH; Ording H; Bendixen D; Islander G; Ranklev Twetman E; Berg K
Clin Genet; 1997 Dec; 52(6):416-21. PubMed ID: 9520251
[TBL] [Abstract][Full Text] [Related]
19. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
[TBL] [Abstract][Full Text] [Related]
20. Functional characterisation of the R2452W ryanodine receptor variant associated with malignant hyperthermia susceptibility.
Roesl C; Sato K; Schiemann A; Pollock N; Stowell KM
Cell Calcium; 2014 Sep; 56(3):195-201. PubMed ID: 25086907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
